Vimarsana
Biggest News Aggregation in the World

Page 45 - Beigene News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Beigene. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Beigene Today - Breaking & Trending Today

BeiGene, Ltd.: BeiGene and EUSA Pharma Announce NMPA Approval of SYLVANT (Siltuximab for Injection) in China for Idiopathic Multicentric Castleman Disease - Vimarsana News

BeiGene, Ltd.: BeiGene and EUSA Pharma Announce NMPA Approval of SYLVANT (Siltuximab for Injection) in China for Idiopathic Multicentric Castleman Disease

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) and EUSA Pharma (UK), Ltd. today announced that the China National Medical Products Administration (NMPA) has approved SYLVANT(siltuximab for injection) for

BeiGene Announces Approval of BRUKINSA (zanubrutinib) in the European Union for Treatment of Adults with Waldenström's Macroglobulinemia - Vimarsana News

BeiGene Announces Approval of BRUKINSA (zanubrutinib) in the European Union for Treatment of Adults with Waldenström's Macroglobulinemia

EU approval follows recent approvals for BRUKINSAincluding U.S., China, Brazil, and Canada The approval is based on Phase 3 ASPEN head-to-head trial comparing BRUKINSA against ibrutinib BeiGene

Fierce Pharma Asia—Legend, J&J's CAR-T delay; BeiGene's Brukinsa data; Samsung Biologics CEO interview - Vimarsana News

Fierce Pharma Asia—Legend, J&J's CAR-T delay; BeiGene's Brukinsa data; Samsung Biologics CEO interview

Legend Biotech and Johnson & Johnson have to wait three more months for an FDA decision on their CAR-T medicine. BeiGene's Brukinsa posts competitive frontline leukemia data as key BTK showdown nears. Samsung Biologics' newly minted CEO talks about the CDMO's rapid expansion. And more.

Shoreline Biosciences secures $140M for off-the-shelf NK cell therapies for cancer - Vimarsana News

Shoreline Biosciences secures $140M for off-the-shelf NK cell therapies for cancer

Gilead Sciences and BeiGene, which started research alliances with Shoreline Biosciences earlier this year, are among the investors in the biotech's latest financing. The preclinical-stage company technology develops cell therapies for cancer by using natural killer cells.

Fierce Pharma Asia—Takeda's cell, gene therapy deals; BMS-BeiGene Abraxane brawl - Vimarsana News

Fierce Pharma Asia—Takeda's cell, gene therapy deals; BMS-BeiGene Abraxane brawl

Takeda doubles down in cell and gene therapy with new deals with Immusoft and Poseida Therapeutics. Bristol Myers Squibb is pulling the plug on its Abraxane China licensing deal with BeiGene amid legal tension. And more.